A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity, and health care costs of chronic hepatitis b in China

Value in Health Regional Issues

Volumn 2, Issue 1, 2013, Pages 48-56

  Wei, Lai ^a   Hu, Shanlian ^b   Hou, Jinlin ^c   Liu, Gordon ^d   Ren, Hong ^e   Duan, Zhongping ^f   Xie, Qing ^g   Fang, Xiao ^h   Jia, Jidong ⁱ  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d Peking University   (China)

^e CHONGQING MEDICAL UNIVERSITY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g SHANGHAI JIAO TONG UNIVERSITY   (China)

^h Monitor Deloitte China   (China)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adefovir; Chronic hepatitis B; Cost benefit; Entecavir; Lamivudine; Telbivudine

Indexed keywords

ADEFOVIR; ENTECAVIR; GENERIC DRUG; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE;

ARTICLE; CHINA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG COST; FOLLOW UP; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEPATITIS B; HUMAN; LONGITUDINAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD;

EID: 84877148675     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2013.02.002     Document Type: Article

References (54)

1. Zhuang H. Hepatitis B epidemiology research update. Chin J Front Med Sci (Electronic Version) 2009, 2. Available from http://www.cnki.com.cn/Article/CJFDTotal-YXQY200902010.htm. [Accessed April 10, 2013].
2. Lu F.M., Zhuang H. Management of hepatitis B in China. Chin Med J 2009, 122:1-2.
3. Chen C.J., Yang H.I., Ileoje U.H., et al. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009, 49(Suppl):S72-S84.
4. Liaw Y.F., Leung N., Kao J.H., et al. Asia-pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
5. Guideline on prevention and treatment of chronic hepatitis B in China. Chin Med J 2010;120:2159-73.
6. Chronic Hepatitis B Practice Survey: Shanghai, China. Synovate Healthcare, 2009.
7. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
8. Lok A., McMahon B.J. AASLD practice guideline update-chronic hepatitis B: update 2009. Hepatology 2009, 50:1-35.
9. Ide T., Sata M., Chayama K., et al. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010, 4:594-600.
10. Korean Association for the Study of Liver. The Korean Association for the Study of Liver Treatment guideline. 2011.
11. Park J.Y., Heo J., Lee T.J. A novel estimation of the relative economic value in terms of different HBV treatment options in Korea. Korean J Hepatol 2011, 17(Suppl):S21.
12. Chen C.J., Yang H.I., Su J., et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (REVEAL-HBV). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
13. Iloeje U.H., Yang H.I., Su J., et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
14. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
15. Veenstra D.L., Sullivan S.D., Clarke L., et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007, 25:963-977.
16. Antoniou T., Raboud J., Chirhin S., et al. Incidence of and risk factors for Tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005, 6:284-290.
17. Idris B.I., Brosa M., Richardus J.H., et al. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol 2008, 20:320-326.
18. Kanwal F., Farid M., Martin P., et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006, 101:2076.
19. Kim W.R., Poterucha J.J., Kremers W.K., et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10:968-974.
20. Xu B., Hu D.C., Rosenberg D.M., et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003, 18:1345-1352.
21. Crowley S.J., Tognarini D., Desmond P.V., Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000, 17:409-427.
22. Crowley S., Tognarini D., Desmond P., et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002, 17:153-164.
23. Hou J., Jia J., Chen C., et al. Efficacy and safety of entecavir treatment in adefovir-experienced CHB patients in real-life setting in China. Presented at: The 21st Conference of the Asia Pacific Association for the Study of the Liver. Bangkok, Thailand. February 17-21, 2011. Poster PP05.152.
24. Chang T.T., Gish R.G., De Man R.A. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
25. Gish R.G., Lok A.S., Chang T.T. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437-1444.
26. Lai C.L., Shouval D., Lok A.S. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1120.
27. Chang T.T., Lai C.L., Chen C.J. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. Hepatology 2004, 19:1276-1282.
28. Lai C.L., Gene E., Liaw Y.F. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
29. Liaw Y.F., Gene E., Leung N. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
30. Hsu C.W., Chen Y.C., Liaw Y.F. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. J Hepatol 2009, 50(Suppl):S331-S337.
31. Jia J.D., Gane E., Wang Y.M., et al. Prolonged efficacy and safety of 4 years continuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies. Presented at: The 20th Conference of the Asia Pacific Association for the Study of the Liver. Beijing, China. March 23-25, 2010. Poster FP-090.
32. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 year. Gastroenterology 2006, 131:1743-1751.
33. Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
34. Zeng M.D., Mao Y.M., Yao G.B., et al. Five years treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int 2012, 32:137-146.
35. GSK clinical trial report: ADF30001_5. Available from: . [Accessed February 7, 2013]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=ADF30001_5&studyId=196F366C-3597-42F2-8473-58B433C72FF9&compound=adefovir.
36. GSK clinical trial report: ADF106632. Available from: . [Accessed February 7, 2013]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=ADF106632&studyId=EB3D13EA-6386-40B1-B3C9-0842B2685BDE&compound=adefovir.
37. Chang T.T., Lai C.L., Yoon S.K., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
38. Chang T.T., Liaw Y.F., Wu S.S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatits B. Hepatology 2010, 52:886-893.
39. Yao G.B., Chen C.W., Lu W.L., et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatits B: a randomized double-blinded trial in China. Hepatol Int 2007, 1:365-372.
40. Shouval D., Lai C.L., Chang T.T., et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009, 50:289-295.
41. Yao G.B., Ren H., Xu D.Z., et al. Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. J Viral Hepatitis 2010, 17:51-58.
42. Wong J.B., Koff R.S., Tinè F., Pauker S.G. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995, 122:664-675.
43. Fattovich G., Pantalena M., Zagni I., et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002, 97:2886-2895.
44. Yang Z.J. Economic analysis on the prevention, monitoring and treatment of chronic infectious disease in China-a case study of chronic hepatitis B 2008, Shanghai Jiaotong University.
45. Hu M., Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 2009, 12(Suppl):S89-S92.
46. But D.Y., Yuen M.F., Fung J., Lai C.L. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010, 9:821-829.
47. Fleischer R.D., Lok A.S. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009, 51:787-791.
48. Lui Y.Y., Chan H.L. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther 2009, 7:259-268.
49. Levy A.R., Kowdley K.V., Iloeje U.H., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008, 11:527-538.
50. Wu B., Le T., Chen H., et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010, 13:592-600.
51. Sung J.J.Y., Lai J.Y., Zeuzum S., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
52. Yuan Y., Iloeje U., Li H., et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese social security program. Value Health 2008, 11(Suppl):S11-S22.
53. Ha N.B., Ha N.B., Garcia R.T., et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009, 50:727-734.
54. Izzedine H., Hulot J.S., Launay-Vacher V., et al. Adefovir Dipivoxil International 437 Study Group; Adefovir Dipivoxil International 438 Study Group. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004, 66:1153-1158.